TORONTO — Cannabis company Organigram Global Inc. has posted record quarterly revenues, and the company credits a major European acquisition for the milestone. The Toronto-based firm says its expansion into the European market is already paying off financially. As a result, Organigram now stands out as one of the strongest performers in the cannabis sector this year.

How the European Deal Boosted Organigram’s Revenue

In April, Organigram acquired Germany-based Sanity Group GmbH, a medical cannabis company. This acquisition added roughly $38 million in net revenue during the three-month period ending June 30. Consequently, the deal quickly became a key driver of the company’s overall financial performance.

Organigram had already held a stake in Sanity Group before the full buyout. However, in April, the company acquired all of Sanity’s remaining issued and outstanding shares. This purchase cost approximately 107 million euros, which equals about $173.7 million. Therefore, the move represented a significant financial commitment toward European growth.

Furthermore, Sanity Group is not stopping at Germany. The company is actively pursuing a broader European growth strategy. Specifically, it plans to expand operations into Switzerland, Poland, and the U.K. As a result, Organigram’s European footprint could grow substantially in the coming quarters.

Organigram’s Quarterly Financial Results

Organigram’s net revenue reached $105.8 million for the quarter. In comparison, the company earned $70.8 million during the same period last year. Thus, revenue nearly grew by half year-over-year, marking a notable financial turnaround.

Meanwhile, the company’s net income also improved dramatically. Organigram reported a net income of $105.5 million this quarter. In contrast, the company posted a net loss of $6.3 million during the third quarter of 2025. Therefore, this shift from loss to substantial profit highlights the strength of the company’s current strategy.

Organigram’s Canadian operations also continued to perform well. Specifically, the company maintained market leadership while improving results in key product categories. Meanwhile, the newly acquired European business is aligning closely with expectations.

What Organigram’s CEO Had to Say

Organigram CEO James Yamanaka addressed the company’s performance directly. According to Yamanaka, both the European and Canadian segments are contributing positively to overall results. In his statement, he said: “Sanity’s performance has been in line with our expectations, while our Canadian business continues to demonstrate resilience through market leadership and improving performance in key categories.”

His comments suggest that Organigram’s dual-market approach is working as intended. Additionally, the company appears confident about sustaining this momentum. As Sanity Group’s European expansion continues, analysts will likely watch closely for further growth signals.

Overall, Organigram’s latest results reflect a company in transition. Specifically, it is shifting from a primarily Canadian cannabis producer into an international player. Given the current trajectory, the European acquisition may continue to shape the company’s revenue growth in future quarters.